Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

Brett S. Carver(Kettering University), Jennifer Tran(Memorial Sloan Kettering Cancer Center), Anuradha Gopalan(Memorial Sloan Kettering Cancer Center), Zhenbang Chen(Cancer Genetics (United States)), Safa Shaikh(Memorial Sloan Kettering Cancer Center), Arkaitz Carracedo(Memorial Sloan Kettering Cancer Center), Andrea Alimonti(Memorial Sloan Kettering Cancer Center), Caterina Nardella(Beth Israel Deaconess Medical Center), Shohreh Varmeh(Cancer Genetics (United States)), Peter T. Scardino(Memorial Sloan Kettering Cancer Center), Carlos Cordon‐Cardo(Columbia University), William L. Gerald(Memorial Sloan Kettering Cancer Center), Pier Paolo Pandolfi(Cancer Genetics (United States))
Nature Genetics
April 26, 2009
10.1038/ng.370
Cited by 660Open Access
Full Text

Abstract

Related Papers

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Zhenbang Chen, Lloyd C. Trotman, David R. Shaffer et al.|Nature|2005|2k
Pten is essential for embryonic development and tumour suppression
Antonio Di Cristofano, Bárbara Pesce, Carlos Cordon‐Cardo et al.|Nature Genetics|1998|1.5k
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Scott A. Tomlins, Bharathi Laxman, Saravana M. Dhanasekaran et al.|Nature|2007|843
Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Scott A. Tomlins, Bharathi Laxman, Sooryanarayana Varambally et al.|Neoplasia|2008|698
SIR2 and SIR4 interactions differ in core and extended telomeric heterochromatin in yeast.
Sabine Strahl‐Bolsinger, Andreas Hecht, Kang Luo et al.|Genes & Development|1997|670